dc.contributor.author | Khanolkar, Rahul Chaitanya | |
dc.contributor.author | Zhang, Chu | |
dc.contributor.author | al-Fatyan, Farah | |
dc.contributor.author | Lawson, Linda G | |
dc.contributor.author | Depasquale, Ivan | |
dc.contributor.author | Meredith, Fiona | |
dc.contributor.author | Muller, Frank | |
dc.contributor.author | Nicolson, Marianne | |
dc.contributor.author | Dahal, Lekh Nath | |
dc.contributor.author | Abu Eid, Rasha | |
dc.contributor.author | Rajpara, Sanjay | |
dc.contributor.author | Barker, Robert Norman | |
dc.contributor.author | Ormerod, Anthony | |
dc.contributor.author | Ward, Frank James | |
dc.date.accessioned | 2022-01-07T00:07:10Z | |
dc.date.available | 2022-01-07T00:07:10Z | |
dc.date.issued | 2022-01-05 | |
dc.identifier.citation | Khanolkar , R C , Zhang , C , al-Fatyan , F , Lawson , L G , Depasquale , I , Meredith , F , Muller , F , Nicolson , M , Dahal , L N , Abu Eid , R , Rajpara , S , Barker , R N , Ormerod , A & Ward , F J 2022 , ' TGFb2 induces the soluble isoform of CTLA-4 – implications for CTLA-4 based checkpoint inhibitor antibodies in malignant melanoma ' , Frontiers in Immunology , vol. 12 , 763877 . https://doi.org/10.3389/fimmu.2021.763877 | en |
dc.identifier.issn | 1664-3224 | |
dc.identifier.other | PURE: 210105818 | |
dc.identifier.other | PURE UUID: d1266e03-83d2-4376-a11b-02bfd5b90d9c | |
dc.identifier.other | Scopus: 85123167616 | |
dc.identifier.uri | https://hdl.handle.net/2164/17798 | |
dc.description | FUNDING This work was funded by the Chief Scientist’s office, Scotland grant no. ETM/280. Acknowledgments Microscopy was performed in the Microscopy and Histology Core Facility at the University of Aberdeen. Flow cytometry was performed in the Iain Fraser Cytometry Centre. We are very grateful to our lab manager Ms. Gill Moir for her assistance with this work and also to the many BSc/MSc project students who worked on this project. We are extremely grateful for all of the volunteer melanoma patient donors and healthy donors that supported this work. FA-F received an Elphinstone PhD scholarship funded by the School of Medicine, Medical Sciences & Nutrition at the University of Aberdeen. | en |
dc.format.extent | 14 | |
dc.language.iso | eng | |
dc.relation.ispartof | Frontiers in Immunology | en |
dc.rights | This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.https://creativecommons.org/licenses/by/4.0/ | en |
dc.subject | SDG 3 - Good Health and Well-being | en |
dc.subject | checkpoint inhibitor | en |
dc.subject | CTLA-4 (cytotoxic T lymphocyte-associated antigen 4) | en |
dc.subject | sCTLA-4 | en |
dc.subject | melanoma | en |
dc.subject | TGFb2 | en |
dc.subject | T cells | en |
dc.subject | R Medicine | en |
dc.subject | Chief Scientist Office (CSO) | en |
dc.subject | ETM/280 | en |
dc.subject | Supplementary Data | en |
dc.subject.lcc | R | en |
dc.title | TGFb2 induces the soluble isoform of CTLA-4 – implications for CTLA-4 based checkpoint inhibitor antibodies in malignant melanoma | en |
dc.type | Journal article | en |
dc.contributor.institution | University of Aberdeen.Medical Education | en |
dc.contributor.institution | University of Aberdeen.Applied Medicine | en |
dc.contributor.institution | University of Aberdeen.Dental Education | en |
dc.contributor.institution | University of Aberdeen.Institute of Medical Sciences | en |
dc.contributor.institution | University of Aberdeen.Data Safe Haven | en |
dc.contributor.institution | University of Aberdeen.Medical Sciences | en |
dc.description.status | Peer reviewed | en |
dc.description.version | Publisher PDF | en |
dc.identifier.doi | https://doi.org/10.3389/fimmu.2021.763877 | |
dc.identifier.vol | 12 | en |